We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
-22.52%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$1.18B
AUM Growth
-$1.05B
Cap. Flow
-$488M
Cap. Flow %
-41.25%
Top 10 Hldgs %
68.01%
Holding
52
New
5
Increased
2
Reduced
19
Closed
12

Top Buys

Rank Stock Value
1
WGS icon
GeneDx Holdings
WGS
+$23.5M
2
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$9.77M
3
ABCL icon
AbCellera Biologics
ABCL
+$6.35M
4
CLDX icon
Celldex Therapeutics
CLDX
+$4.79M
5
RLAY icon
Relay Therapeutics
RLAY
+$4.53M

Top Sells

Rank Stock Value
1
PACB icon
Pacific Biosciences
PACB
+$72.7M
2
NVTA
Invitae Corporation
NVTA
+$49.4M
3
EXAS
Exact Sciences
EXAS
+$47.1M
4
CDNA icon
CareDx
CDNA
+$42.7M
5
FATE icon
Fate Therapeutics
FATE
+$35.9M

Sector Composition

Rank Sector Weight
1 Healthcare 99.79%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EQRX
1
DELISTED
EQRx, Inc. Common Stock
EQRX
$185M 15.67%
39,527,669
– –
ALNY icon
2
Alnylam Pharmaceuticals
ALNY
$29.1B
$117M 9.93%
805,000
-195,000
-20% -$27.7M
BLFS icon
3
BioLife Solutions
BLFS
$1.56B
$104M 8.83%
7,566,292
– –
RLAY icon
4
Relay Therapeutics
RLAY
$4.04B
$68.1M 5.76%
4,068,574
+211,321
+5% +$4.53M
MXCT icon
5
MaxCyte
MXCT
$116M
$66.1M 5.59%
13,971,334
– –
BPMC
6
DELISTED
Blueprint Medicines
BPMC
$58.1M 4.91%
1,150,000
-400,000
-26% -$23.4M
SLGC
7
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
$56M 4.73%
12,389,082
– –
FATE icon
8
Fate Therapeutics
FATE
$294M
$52M 4.4%
2,100,000
-1,300,000
-38% -$35.9M
SRPT icon
9
Sarepta Therapeutics
SRPT
$1.63B
$48.7M 4.12%
650,000
-150,000
-19% -$11M
VERV
10
DELISTED
Verve Therapeutics
VERV
$48M 4.05%
3,138,167
– –
RVMD icon
11
Revolution Medicines
RVMD
$38.8B
$46.2M 3.91%
2,370,000
– –
DNLI icon
12
Denali Therapeutics
DNLI
$3.67B
$44.1M 3.73%
1,500,000
– –
IPSC icon
13
Century Therapeutics
IPSC
$355M
$26.9M 2.28%
3,206,380
– –
ABSI icon
14
Absci
ABSI
$1.35B
$25.6M 2.17%
7,718,593
– –
GBT
15
DELISTED
Global Blood Therapeutics, Inc.
GBT
$25.6M 2.16%
800,000
-525,000
-40% -$15.4M
WGS icon
16
GeneDx Holdings
WGS
$1.98B
$20.7M 1.75%
498,106
+346,591
+229% +$23.5M
TNYA icon
17
Tenaya Therapeutics
TNYA
$162M
$20.2M 1.71%
3,586,818
– –
EXAS
18
DELISTED
Exact Sciences
EXAS
$17.7M 1.5%
450,000
-880,000
-66% -$47.1M
TWST icon
19
Twist Bioscience
TWST
$5.98B
$17.5M 1.48%
500,000
-380,000
-43% -$13.5M
AGIO icon
20
Agios Pharmaceuticals
AGIO
$1.84B
$17.4M 1.47%
785,000
-1,305,000
-62% -$29.5M
TNGX icon
21
Tango Therapeutics
TNGX
$4.43B
$15.9M 1.34%
3,500,000
-1,987,910
-36% -$12M
BEAM icon
22
Beam Therapeutics
BEAM
$2.66B
$14.5M 1.23%
375,000
-443,820
-54% -$17.6M
GH icon
23
Guardant Health
GH
$21.7B
$11M 0.93%
272,500
-147,500
-35% -$7.31M
KRTX
24
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$10.8M 0.91%
+85,000
New +$9.77M
TSVT
25
DELISTED
2seventy bio
TSVT
$8.12M 0.69%
614,754
– –
1
2 3

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MIM
Marco Investment Management Atlanta, Georgia $1.33B AUM 32.43% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
MCM
Mill Capital Management Concord, North Carolina $1.31B AUM 17.4% 1-Year Est. Return
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return

Casdin Capital's Q2 2022 Portfolio in Review

As of Q2 2022, Casdin Capital held 52 positions worth $1.18B, down 47% from $2.23B the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Casdin Capital withdrew a net $488M in Q2 2022, closing 12 positions and reducing 19 holdings. Its most notable exit was Pacific Biosciences, an estimated $72.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 96% a quarter earlier.

Against the trend, Casdin Capital opened a new position in Karuna Therapeutics, Inc. Common Stock worth $10.8M.

  • Casdin Capital's largest Q2 2022 buy was Karuna Therapeutics, Inc. Common Stock: 85,000 shares worth $10.8M.
  • Casdin Capital added most to GeneDx Holdings in Q2 2022, an estimated $23.5M increase.
  • Casdin Capital's biggest Q2 2022 reduction was Invitae Corporation, cutting an estimated $49.4M.
  • Casdin Capital fully exited Pacific Biosciences in Q2 2022, selling an estimated $72.7M.
  • Casdin Capital's ten largest holdings make up 68% of its $1.18B portfolio in Q2 2022.
  • Casdin Capital opened 5 new positions and closed 12 in Q2 2022.
  • Casdin Capital's portfolio value fell 47% quarter-over-quarter to $1.18B.

Based on Casdin Capital's 13F filing for Q2 2022, filed 15 Aug 2022.